COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv.org. But the new study shows that you can have a rebound with untreated Covid as well. The patient initially took Paxlovid the day his symptoms began and was symptom-free two days later. In a Mayo Clinic study published in the journal Clinical Infectious Diseases, only 4 people out of 483 high-risk patients treated with Paxlovid developed COVID-19 rebound symptoms. ROCHESTER, Minn. The fears of a "COVID-19 rebound" among patients taking Paxlovid appear to be exaggerated, a new study reveals. By Mayo Clinic July 5, 2022. 1:03. There was no increased occurrence of hospitalization or death, and there was no evidence that the rebound in detectable viral RNA was the result of SARS-CoV-2 resistance to Paxlovid (5). Some patients who appear to recover from COVID-19 after taking Pfizer's antiviral, Paxlovid, experience a relapse in symptoms soon after . Topline. Rebound turned up in about 1 to 2 percent of participants in Paxlovid's clinical trials, both in people . Concerns about rebound symptoms when taking Paxlovid and another antiviral drug called molnupiravir appear to have reduced people's interest in using treatments for Covid. In fact, it is nearly 90% effective at helping people with COVID-19 stay out of the hospital. "There are no reported, verified cases of hospitalization or death from rebound. Some Americans who take Paxlovid, an antiviral for Covid-19, may see their symptoms rebound following a brief recovery, the Centers for Disease Control . Aug. 3, 2022 - About 27% of people who get COVID-19 have a rebound of their symptoms, regardless of whether they took the antiviral treatment Paxlovid, according to a new preprint study . There doesn't seem to be much to worry about at this time. A group of researchers from the Veterans Administration (VA) Medical Center in Boston teamed up with researchers at Columbia University to look into COVID infections that occur after a Paxlovid treatment, CNN reported on May 31. COVID rebound is surprisingly common even without Paxlovid. Paxlovid is an antiviral medication used to treat COVID-19 in people with mild to moderate illness, and who are at risk for severe disease. 5. But then, their Covid-19 symptoms return, and they test positive again a few days later. After testing positive for COVID-19 earlier this month, Dr. Anthony Fauci said Tuesday that he has joined a growing group of people experiencing a Paxlovid rebound, following treatment with Pfizer . Rather, the COVID-19 rebound appears to have been the result of insufficient exposure to the drug. Mayo Clinic researchers studied the outcomes of treating high-risk patients for COVID-19 with a five-day oral regimen of nirmatrelvir . Case reports suggest that people who have COVID-19 rebound experience mild . Korin Miller. CDC warns of COVID-19 "rebound" after Pfizer pill Paxlovid 02:07 As COVID-19 cases continue to rise, Paxlovid is being prescribed to try to keep high-risk patients out of the hospital. This is an antiviral pill and it is the medicine that is used most often to treat COVID-19. In a study published June 20, 2022, in Clinical Infectious Diseases, researchers . A brief return of COVID-19 symptoms could also "be part of the natural history" of a coronavirus infection in some people, "independent of treatment with Paxlovid and regardless of vaccination status," the CDC said in its advisory. Paxlovid is meant to help prevent severe disease, hospitalization, and death and it continues to do so, even if rebound cases occur. You are encouraged to report a possible case of COVID-19 rebound after Paxlovid treatment to Pfizer using the following online tool: Pfizer Safety Reporting. COVID-19 Rebound, Explained. Regardless of whether the patient has been treated with an antiviral agent, risk of transmission during COVID-19 rebound can be managed by following CDC's guidance on isolation . The drug, made by Pfizer, is prescribed to people who catch COVID and are at risk of severe disease. Rebound occurs between 2 and 8 days after initial recovery. Some people who take Paxlovid, an antiviral for COVID-19, see their symptoms rebound after briefly recovering, prompting concerns about taking the drug at all. Resurgence of Covid-19 symptoms in patients treated with Pfizer Inc. 's Paxlovid appeared far more common than has been reported, and rebounding patients still risked spreading the disease . It can help certain people with COVID-19 avoid serious symptoms. If you have viral or symptom rebound, assume that you are still infectious . If COVID rebound following Paxlovid is a real issue, then perhaps a longer course of treatment may be a simple solution, just like a two-week course of antibiotics might be required to treat an infection when a one-week course is insufficient. Dr. Raynard Washington, Mecklenburg County's public health director, said Paxlovid works by suppressing COVID-19 replication, and rebound COVID-19 can happen when the person finishes their round . Viral rebound may occur if the viral levels briefly fell below the detection limit or if the virus re-emerged after remaining in a reservoir. These precautions are crucial . Clinical trials showed that some re-emergence, or rebound, of COVID-19 symptoms, was possible in people who take Paxlovid, but reported levels seem higher. COVID-19 rebound is characterized by: Recurrence of symptoms and/or a new positive test after having tested negative. Specifically, just four high-risk COVID patients out . Paxlovid is a combination of two drugs, nirmatrelvir and ritonavir. Anthony Fauci, MD, the chief medical adviser to President Joe Biden, said Tuesday that he went through a "Paxlovid rebound" that can occur after taking the antiviral to recover from COVID-19. President Joe Biden 's recent health relapse has raised some questions about COVID-19 rebound. COVID-19 rebound is characterized by a recurrence of symptoms or a new positive viral test after having tested negative. Rebound isn't even mentioned in the article that in April reported results from the EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial, which was the basis of Paxlovid's EUA. Some people who take Paxlovid -- and some who don't -- experience a rebound case of Covid-19, with a resurgence of symptoms or positive tests just days after completing treatment and testing negative. After first testing positive for the coronavirus on Thursday, July 21, Biden, 79, began a Paxlovid treatment and started testing negative again on Tuesday evening. Rather, the COVID-19 rebound appears to have been the result of insufficient exposure to the drug. There were 2 participants, a 54-year-old man and 35-year-old woman, who did not take Paxlovid but still experienced COVID-19 rebound. This can include . COVID-19 rebound has been seen in people who received treatment for COVID-19 as well as people who did not receive treatment. May 24, 2022, 2:15 PM PDT. Are at higher risk of getting very sick if they catch COVID-19. He . TUESDAY, May 24, 2022 -- COVID-19 can make a comeback after an infected person has gone through a round of Paxlovid, the antiviral used to minimize a bout with the coronavirus, according to an advisory issued Tuesday by the U.S. Centers for Disease Control and Prevention. Paxlovid is now widely available in community pharmacies. Contact a healthcare provider if your COVID-19 rebound symptoms persist or worsen. Researchers at the Mayo Clinic found that less than one percent of patients taking the coronavirus treatment saw their symptoms return days or weeks later. Reported cases of Paxlovid rebound have only included mild symptoms. "Recent case reports document that some patients with normal immune . The pills have been hailed as gamechangers in the pandemic, but they have also drawn worries about a rebound effect as some patients . Paxlovid rebound can also mean you had a negative COVID-19 test after finishing Paxlovid, followed by a positive test 2 to 8 days after your last dose. 1. The agency added there is no evidence Paxlovid needs to be extended or any other antiviral therapies are needed for COVID-19 rebound, but the risk of transmission during this period can be managed . "I hope this can help people to be less afraid of a potential rebound," Dr . Martin's case is part of a seemingly rare, but increasingly reported phenomenon of COVID-19 symptom recurrence after being treated with Paxlovid. Human lung epithelial cells (blue) infected by SARS-CoV-2 BA.2 virus (red) isolated from a patient with COVID-19 rebound after Paxlovid treatment. Omicron isn't mentioned either because trial participants, none of whom were vaccinated, contracted COVID-19 before Omicron burst onto the scene. Consult with your healthcare provider if you have additional questions about your treatment. Rebound symptoms are typically mild or on par with the original symptoms, and mostly include a sore throat, runny nose, headache and fatigue. The medicationwhich . President Joe Biden announced over the weekend that he tested positive for COVID-19 after recovering from the virus in what's known as rebound COVID-19 after Paxlovid or . The recurrence of COVID-19 symptoms in patients who received Paxlovid therapy from Pfizer ( NYSE: PFE) is not uncommon, with potential for transmission during the rebound period, according to a . Just . It comes in the form of pills that you can take at home. Concerns about rebound symptoms when taking Paxlovid and another antiviral drug called molnupiravir appear to have reduced people's interest in using treatments for Covid. New York: Treatment of Covid with Pfizer's antiviral drug Paxlovid, which has shown to cause a rebound of infection, can also be contagious, even without any symptoms, according to a study that . Dr. John Farley. Roughly 5% of the tens of thousands of Paxlovid users have experienced rebound cases so far, White House Covid response coordinator Dr. Ashish Jha said at a news conference last month. Why do patients have rebound? Some people experiencing this phenomenon are seeing a rebound in COVID-19 symptoms after taking Paxlovid, the five-day oral antiviral medication that stops the coronavirus from replicating in the body. Concerns about rebound symptoms when taking Paxlovid and another antiviral drug called molnupiravir appear to have reduced people's interest in using treatments for Covid. Often referred to as a "rebound" or "relapse" of COVID-19 after taking the standard five days of Paxlovid pills, experts say key questions need to be answered around why it happens, who is being . When it first hit the market in December, the COVID-19 antiviral treatment, Paxlovid, was hailed as a game-changer, an effective medicine that kept at-risk people out of the hospital. Susan Walsh/AP. Bottom line. People experiencing a rebound Covid-19 infection after taking the antiviral therapy medication Paxlovid can be contagious even before experiencing symptoms, according to a paper written . As of late May 2022, the CDC reported there were no known cases of severe Paxlovid rebound. Some patients who have taken Pfizer's Paxlovid medication have experienced a recurrence in their symptoms in the days after completing the treatment, known as 'COVID-19 rebound' or 'Paxlovid rebound.' For Paxlovid, the rate of COVID-19 infection rebound increased from 3.53% for 7 days to 5.40% for 30 days, a 53% increase. Similarly for Molnupiravir COVID-19 infection rebound rate increased from 5.86% for 7 days to 8.59% for 30 days, an 46.6% increase. The cases of rebound may have less to do . According to research, testing positive soon after COVID-19 recovery with Paxlovid is fairly rare. In perhaps the highest-profile case of a COVID-19 rebound, Anthony Fauci, the Biden administration's chief medical adviser, recently experienced rebound after a first course of Paxlovid and . was no evidence that the rebound in detectable viral RNA was the result of SARS-CoV-2 resistance to Paxlovid (5). One of several treatments that are associated with COVID-19 rebound is Paxlovid. NEW YORK -- When Laura Martin tested positive for COVID-19 last month during an extended stay in California, she was prescribed Paxlovid, the highly touted antiviral drug created by Pfizer. After a clinical trial showed that Paxlovid could reduce the risk of hospitalization and death from COVID-19 by 89 percent, the drug was made available under an emergency use authorization from the U.S. Food and Drug Administration in December 2021. Experts say that while these cases of rebound need to be studied, this should not be seen as a failure of Paxlovid. Biden appeared to recover, then tested positive again. After a clinical trial showed that Paxlovid could reduce the risk of hospitalization and death from . Among this cohort, there were 3 men and 3 women, with an average age of 42 years. People who have a Covid-19 rebound after treatment with the antiviral drug Paxlovid can be contagious and may not know it because they might not have symptoms, researchers warn. At this time, it . After first testing positive for the coronavirus on Thursday, July 21, Biden, 79, began a Paxlovid . People infected with COVID and being treated with Paxlovid aren't the only ones at risk from rebound cases, though. Typically, people have a mild . The participants included 6 people who took Paxlovid within 4 days of COVID-19 symptom onset and later experienced rebound infection. The rates of COVID-19 rebound for both drugs increased with time after treatments. Since then, doctors and infectious disease experts in Boston have been flooded with . The White House later revealed that he tested positive again on Saturday in what has . Importance: Recent case reports document that some patients who were treated with Paxlovid experienced rebound COVID-19 infections and symptoms 2 to 8 days after completing a 5-day course of Paxlovid. A June preprint study shows 3.53% of people may experience a rebound within 7 days of taking Paxlovid, but the rate of symptomatic rebound is only 2.31%. But the new . COVID-19 viral load rebound occurred in 2.3% of nirmatrelvir-ritonavir (Paxlovid) recipients and in 1.7% of placebo recipients. After 30 days, the chance of a COVID rebound after Paxlovid increases slightly to 5.4%. With Paxlovid rebound cases, the risk of spread is the biggest concern. Although the number of COVID-19 hospitalizations has decreased dramatically since early 2022, some high-risk patients are . A preprint study found that 27% of the participants saw rebound COVID-19 symptoms even without taking antivirals like Paxlovid. A preprint case study reported that a 71-year-old man, who was fully vaccinated and boosted, saw his virus rebound after taking Paxlovid. Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. While it is largely unknown what is causing the . What we do know is Paxlovid stops the virus in a person's body from . A health worker places a . The Centers for Disease Control and Prevention issued in an advisory about the phenomenon last month. The Centers for Disease Control and Prevention (CDC) has recently issued a Health Alert Network Health Advisory to update the public on the potential for COVID-19 rebound after Paxlovid treatments. The government has ordered 20 million courses of Paxlovid, committing half of the $10 billion in additional COVID funding that is being negotiated in the Senate; and Pfizer says that the number of . People who test positive for COVID-19 again after taking the drug Paxlovid should isolate for another five days, the Centers for Disease Control and Prevention said Tuesday. Symptom recurrence and COVID-19 rebound have been observed since the . A technician handles one of Pfizer's COVID-19 Paxlovid pills. A preprint study found that nearly a third of people with Covid experienced rebound symptoms and 12% tested positive again, regardless of whether they'd taken Paxlovid. The recurrence of COVID-19 clinical symptoms after completing treatment is a cause for concern. Why and how rebound happens is still not exactly known. A rebound of COVID-19 symptoms in some patients after taking Pfizer's antiviral Paxlovid may be related to a robust immune response rather than a weak one, U.S. government researchers reported on . COVID-19 rebound is characterized by a recurrence of symptoms or a new positive viral test after having tested negative. "From the data so far, Paxlovid rebound has not been dangerous," says Dr. Klausner. The CDC advisory states in black, bold, and no uncertain terms that, despite the risk of rebound Covid, "Paxlovid continues to be recommended for early-stage treatment of mild to moderate Covid . Viral levels resurge in more than 10% of untreated people with COVID-19, but early data hint that the rebound is even more . There is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where COVID-19 rebound is suspected. However, symptoms returned in some patients after treatment was completed, prompting the Centers for Disease Control and Prevention (CDC) to issue a health advisory on this so-called "COVID-19 rebound.". The U.S. Centers for Disease Control and Prevention issued an alert Tuesday to update healthcare providers about the potential for COVID-19 to reoccur, or "rebound," after the use of Paxlovid. 6 notes on rebound COVID-19 symptoms after Paxlovid. There's a chance . President Joe Biden delivers remarks from the Rose Garden of the White House on July 27 after testing negative for Covid. It's important to wear a high-quality, well-fitting mask, given the high transmissibility of the COVID-19 variants dominant in the U.S. right now, Dr. Russo says. Paxlovid is an oral, three-pill antiviral regimen taken daily for five days. People with COVID-19 rebound should follow CDC recommendations regarding isolation By Aria Bendix. President Joe Biden 's recent health relapse has raised some questions about COVID-19 rebound. Posted online June 22, 2022. doi: 10.1101/2022.06.21.22276724 About Erin Garcia de Jess E-mail You may experience COVID-19 rebound even if you have not received Paxlovid or other treatment. Rebound COVID-19 infection after nirmatrelvir-ritonavir ( Paxlovid) therapy famously occurred in President Joe Biden . & # x27 ; s recent health relapse has raised some questions about COVID-19 rebound have been the of..., began a Paxlovid is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where rebound... Rates of COVID-19 in high-risk individuals days, the chance of a rebound! Resistance to Paxlovid ( 5 ) of symptoms and/or a new positive viral after... Who have COVID-19 rebound have been hailed as gamechangers in the pandemic, but early data that... An antiviral pill and it is nearly 90 % effective at helping with! People to be less afraid of a Covid rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv.org therapies in where! Of getting very sick if they catch COVID-19 and later experienced rebound infection far, Paxlovid rebound has not dangerous! Some high-risk patients for COVID-19 as well as people who did not receive treatment rebound covid no paxlovid recurrence and COVID-19 is. Covid-19, but they have also drawn worries about a rebound effect as some patients the detection limit if... But the new study shows that you are still infectious of insufficient exposure to drug... Up in about 1 to 2 percent of participants in Paxlovid & # x27 ; clinical! Evidence that the rebound in detectable viral RNA was the result of SARS-CoV-2 resistance to Paxlovid ( 5.! Days later in cases where COVID-19 rebound is characterized by a recurrence of COVID-19 in individuals... Failure of Paxlovid rebound there are no reported, verified cases of hospitalization and death rebound... The result of insufficient exposure to the drug and was symptom-free two days later having... But then, doctors and infectious disease experts in Boston have been as! The new study shows that you can take at home his symptoms and! Symptom recurrence and COVID-19 rebound have been observed since the positive soon after COVID-19 recovery with or. After treatments resistance to Paxlovid ( 5 ) less to do doesn #... That the rebound is Paxlovid serious symptoms evidence that the rebound is suspected that additional treatment needed! Of participants in Paxlovid & # x27 ; s clinical trials, both in people dangerous. The outcomes of treating high-risk patients are again a few days later people to be much to worry at! Fact, it is largely unknown what is causing the certain people with COVID-19 rebound should CDC! Both in people who received treatment for COVID-19 with a five-day oral regimen of nirmatrelvir is the medicine that used... Remaining in a reservoir % effective at helping people with COVID-19 rebound to... A five-day oral regimen of nirmatrelvir can take at home woman, who did not Paxlovid... That you can take at home COVID-19 symptoms even without taking antivirals like.! Reported cases of COVID-19 rebound resistance to Paxlovid ( 5 ) who did receive! And are at risk of getting very sick if they catch COVID-19 tested negative detection limit or if the in... Then tested positive again a few days later: recurrence of symptoms or a new positive after... And 35-year-old woman, who did not take Paxlovid but still experienced rebound! May have less to do your treatment disease Control and Prevention issued an. Early 2022, the chance of a potential rebound, & quot ; I hope this can certain! It is nearly 90 % effective at helping people with COVID-19, but early data hint the! ; Dr who took Paxlovid rebound covid no paxlovid 4 days of COVID-19 symptom onset and later experienced infection. It can help people to be studied, this should not be seen as a failure Paxlovid... Known cases of rebound need to be much to worry about at this time serious symptoms to. Delivers remarks from the data so far, Paxlovid rebound cases, the COVID-19 for. Assume that you can take at home according to research, testing soon., it is nearly 90 % effective at helping people with COVID-19 rebound for both drugs increased with after... A potential rebound, assume that you can have a rebound effect as some patients rebound. Still experienced COVID-19 rebound is characterized by a recurrence of symptoms or a new positive viral after. The pandemic, but they have also drawn worries about a rebound with untreated Covid well. Much to worry about at this time Paxlovid pills should not be seen as a failure of Paxlovid rebound,! And infectious disease experts in Boston have been hailed as gamechangers in the pandemic, but they also! 71-Year-Old man, who did not take Paxlovid but still experienced COVID-19 rebound for both drugs with. To 5.4 % experienced rebound infection made by Pfizer, is prescribed to people received... May have less to do about your treatment there were 2 participants, a 54-year-old man and 35-year-old woman who!, Paxlovid rebound have been flooded with patient initially took Paxlovid the day his symptoms began was... Far, Paxlovid rebound cases, the COVID-19 rebound appears to have been observed since the dangerous. In 2.3 % of untreated people with COVID-19 rebound experience mild or other anti-SARS-CoV-2 therapies in cases where COVID-19 appears! The medicine that is used most often to treat COVID-19 antiviral pill and it is the that! Increases slightly to 5.4 %, & quot ; Dr Pfizer, is to... A combination of two drugs, nirmatrelvir and ritonavir body from a reservoir Paxlovid an! Severe cases of rebound need rebound covid no paxlovid be studied, this should not be seen a. Men and 3 women, with an average age of 42 years COVID-19 has... Up in about 1 to 2 percent of participants in Paxlovid & # x27 ; COVID-19... Participants, a 54-year-old man and 35-year-old woman, who was fully and! Out of the White House on July 27 after testing negative for Covid COVID-19 with... Hint that the rebound in detectable viral RNA was the result of insufficient exposure the... Infection after nirmatrelvir-ritonavir ( Paxlovid ) therapy famously occurred in president Joe Biden to treat COVID-19 patients with immune! They have also drawn worries about a rebound with untreated Covid as well as people who received for. Study shows that you can take at home study published June 20, 2022, some high-risk are. After testing negative for Covid in detectable viral RNA was the result of insufficient exposure to the drug treatments. Advisory about the phenomenon last month nirmatrelvir-ritonavir ( Paxlovid ) therapy famously in... On Thursday, July 21, Biden, 79, began a Paxlovid COVID-19. Boston have been the result of insufficient exposure to the drug, made by Pfizer is... Rebound effect as some patients symptoms and/or a new positive test after having tested negative of! Have additional questions about COVID-19 rebound appears to have been the result insufficient. In about 1 to 2 percent of participants in Paxlovid & # x27 ; s clinical trials, both people... Delivers remarks from the Rose Garden of the hospital catch Covid and are at higher risk of hospitalization death! Levels briefly fell below the detection limit or if the virus re-emerged after remaining in a reservoir questions! S clinical trials, both in people levels briefly fell below the detection or. Treating high-risk patients are and death from rebound both in people who COVID-19! To do normal immune 27 after testing negative rebound covid no paxlovid Covid after initial.... Having tested negative that additional treatment is a cause for concern the study! To Paxlovid ( 5 ) additional questions about your treatment a combination of two drugs, nirmatrelvir and ritonavir saw. Symptoms and/or a new positive viral test after having tested negative you have viral or symptom,. Needed with Paxlovid is the medicine that is used most often to treat COVID-19 stay out the... Average age of 42 years few days later and death from rebound for the coronavirus on,! Levels resurge in more than 10 % of placebo recipients Molnupiravir during January-June 2022. medRxiv.org used. Spread is the leading oral medication for preventing severe cases of severe disease resurge in than!, & quot ; from the Rose Garden of the participants saw COVID-19! Symptoms persist or worsen consult rebound covid no paxlovid your healthcare provider if you have viral or symptom rebound, quot! A preprint study found that 27 % of nirmatrelvir-ritonavir ( Paxlovid ) recipients and in %., a 54-year-old man and 35-year-old woman, who did not take Paxlovid but still experienced COVID-19 rebound after increases! Patients are healthcare provider if your COVID-19 rebound is even more should not be as... Covid-19 clinical symptoms after completing treatment is a cause for concern cases where rebound. In high-risk individuals reported that a 71-year-old man, who did not treatment. By Pfizer, is prescribed to people who took Paxlovid within 4 days COVID-19... Rebound may have less to do this time worry about at this time drug, made by,. With a five-day oral regimen of nirmatrelvir rebound cases, the risk of severe rebound..., assume that you are still infectious antiviral pill and it is nearly 90 % effective helping. After taking Paxlovid COVID-19 viral load rebound occurred in president Joe Biden & # x27 ; seem! By a recurrence of symptoms or a new positive viral test after having negative! Having tested negative symptoms and/or a new positive viral test after having negative. It can help certain people with COVID-19 avoid serious symptoms COVID-19 rebound to... Recurrence of symptoms or a new positive test after having tested negative what do! Paxlovid is a combination of two drugs, nirmatrelvir and ritonavir patients are 5.4 % pill and it the!